tbuckley/cabot-search huggingface dataset:
Multiparameter Analysis Identifies Heterogeneity in Knee Osteoarthritis Synovial Responses
Authors: Hannah Labinsky, Paul M. Panipinto, Kaytlyn A. Ly, Deric K. Khuat, Bhanupriya Madarampalli, Vineet Mahajan, Jonathan Clabeaux, Kevin MacDonald, Peter J. Verdin, Jane H. Buckner, Erika H. Noss
Journal: Arthritis & Rheumatology (2019)

Objective Synovial membrane inflammation is common in osteoarthritis ( OA ) and increases cartilage injury. However, synovial fluid and histology studies suggest that OA inflammatory responses are not homogeneous. Greater understanding of these responses may provide new insights into OA disease mechanisms. We undertook this study to develop a novel multiparameter approach to phenotype synovial responses in knee OA . Methods Cell composition and soluble protein production were measured by flow cytometry and multiplex enzyme‐linked immunosorbent assay in synovium collected from OA patients undergoing knee replacement surgery (n = 35). Results Testing disaggregation conditions showed that aggressive digestion improved synovial cell yield and mesenchymal staining by flow cytometry, but it negatively impacted CD 4+ T cell and CD 56+ natural killer cell staining. Less aggressive digestion preserved these markers and showed highly variable T cell infiltration (range 0–43%; n = 32). Correlation analysis identified mesenchymal subpopulations associated with different nonmesenchymal populations, including macrophages and T cells ( CD 45+ CD 11b+ HLA − DR + myeloid cells with PDPN + CD 73+ CD 90− CD 34− mesenchymal cells [r = 0.65, P &lt; 0.0001]; and CD 45+ CD 3+ T cells with PDPN + CD 73+ CD 90+ CD 34+ mesenchymal cells [r = 0.50, P = 0.003]). Interleukin‐6 ( IL ‐6) measured by flow cytometry strongly correlated with IL ‐6 released by ex vivo culture of synovial tissue (r = 0.59, P = 0.0012) and was highest in mesenchymal cells coexpressing CD 90 and CD 34. IL ‐6, IL ‐8, complement factor D, and IL ‐10 release correlated positively with tissue cellularity ( P = 0.0042, P = 0.018, P = 0.0012, and P = 0.038, respectively). Additionally, increased CD 8+ T cell numbers correlated with retinol binding protein 4 ( P = 0.033). Finally, combining flow cytometry and multiplex data identified patient clusters with different types of inflammatory responses. Conclusion We used a novel approach to analyze OA synovium, identifying patient‐specific inflammatory clusters. Our findings indicate that phenotyping synovial inflammation may provide new insights into OA patient heterogeneity and biomarker development.
Four-Year Interim Analysis of Miroir, a French Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma
Authors: Olivier Decaux, Margaret Macro, Sophie Gourgou, Florence Lachenal, Caroline Bureau Lenoir, Bertrand Arnulf, Denis Caillot, Anne-Marie Stoppa, Laure Vincent, Arnaud Jaccard, Philippe Moreau, Aurore Perrot, Mohamad Mohty, Lionel Karlin, Cécile Fohrer, Jean-Richard Eveillard, Jean Fontan, Xavier Leleu, Cyrille Hulin, Choquet Sylvain
Journal: Blood (2019)
Maternal Syndrome in Hydrops Foetalis
Authors: C. K. Vartan
Journal: BMJ (1964)

BRiTisH 877 1,400 units the patient was having strong con- tractions lasting 50-60 seconds every 90 seconds.The remnants of the, tablets were removed.Pethilorfan (pethidine hydrochloride and levallorphan tartrate), 150 mg., was given intra- muscularly.The contractions continued at the same frequency, the second stage being com- plete 50 minutes later.The foetal heart rate was regular.The baby cried lustily on arrival.The secundines were delivered complete in 10 minutes.Steady vaginal bleeding continued in spite of a well-contracted uterus and further ergometrine.The patient felt faint and
Surgery of the Esophagus
Authors: John W. Strieder
Journal: New England Journal of Medicine (1950)

IT IS noteworthy that in the year 1950, a Medical Progress report should be concerned solely with the surgery of the esophagus — noteworthy because only fifteen years ago, Churchill1 recalled that the esophagus had been termed one of "the last frontiers of surgery" in a discussion of the unsuccessful operations that had been performed on this organ up to that time. The surgery of that era was concerned with esophagoscopy and the removal of foreign bodies from the esophagus, bougienage for strictures and cardiospasm, the two-stage removal of diverticula of the cervical segment and some disheartening attempts to duplicate . . .
Role of Circulating Myeloid-Derived Suppressor Cell (MDSC) in Hodgkin Lymphoma (HL) Patients: Prospective Study
Authors: Olga Novosad, Oleksandr Gorbach, Oksana Skachkova, Ian Pastushenko, Kateryna Ulianchenko, Nataliia Khranovska, Tetiana Skrypets, Irina Kryachok
Journal: Blood (2019)
On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies ("Inhibitors") Directed Against Therapeutic Factor VIII Proteins (tFVIIIs): Evidence from the PATH Study
Authors: Vincent P. Diego, Bernadette W. Luu, Afshin Ameri, Meera B. Chitlur, Marcio A. Almeida, Karin Haack, Satish Kumar, Long V. Dinh, Henry Mead, Jerry S. Powell, Miguel A. Escobar, Raja Rajalingam, Sarah Williams-Blangero, Carol K. Kasper, Laura Almasy, Shelley Cole, John Blangero, Tom E. Howard
Journal: Blood (2019)
Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse
Authors: Koji Sasaki, Hagop M. Kantarjian, Farhad Ravandi, Nicholas J. Short, Partow Kebriaei, Xuelin Huang, Michael E. Rytting, Nitin Jain, Marina Y Konopleva, Guillermo Garcia-Manero, Richard E. Champlin, Tapan M. Kadia, Jorge E. Cortes, Zeev E. Estrov, Koichi Takahashi, Christopher Loiselle, Corabelle Encarnacion, Meagan Rostykus, Rita Khouri, Patrice Nasnas, Jovitta Jacob, Monica Kwari, Rebecca Garris, Elias Jabbour
Journal: Blood (2019)
Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Authors: Paul M. Barr, Alessandra Tedeschi, Talha Munir, Peter Hillmen, Jennifer Woyach, John C. Byrd, Paolo Ghia, Stephen Mulligan, Sandra Dai, Carlos Amaya-Chanaga, James P. Dean, Susan M. o'Brien
Journal: Blood (2019)
Real World Population-Based Exploration of the Pathology Subtyping and Treatment-Modalities of Diffuse Large B-Cell Lymphoma in Belgium in Relation to Survival
Authors: Willem Daneels, Michael Rosskamp, Gilles Macq, Estabraq Ismael Saadoon, Anke De Geyndt, Fritz Offner, Helene A. Poirel
Journal: Blood (2019)
A Novel Protease-Mediated Chimeric Antigen Receptor (CAR): "Double-Arm" CAR-T Cell System Improves Target Specificity of CAR-T Cell Therapy
Authors: Satoru Aoyama, Shunichiro Yasuda, Daisuke Watanabe, Hiroki Akiyama, Yoshihiro Umezawa, Ayako Nogami, Osamu Miura, Norihiko Kawamata
Journal: Blood (2019)
Predictive Model of Early Relapse in Newly Diagnosed Multiple Myeloma: Analysis from a Pooled Dataset
Authors: Gian Maria Zaccaria, Andrea Capra, Maria Teresa Petrucci, Massimo Offidani, Vittorio Montefusco, Francesco Di Raimondo, Annalisa Bernardini, Anna Marina Liberati, Paola Omedé, Donato Mannina, Tommaso Caravita di Toritto, Vittorio Emanuele Muccio, Nicola Cascavilla, Stefania Montani, Francesca Patriarca, Giulia Benevolo, Elona Saraci, Angelo Belotti, Gianluca Gaidano, Giorgina Specchia, Arnon Nagler, Roman Hajek, Andrew Spencer, Pieter Sonneveld, Mario Boccadoro, Francesca Gay
Journal: Blood (2019)
The diagnostic accuracy of brief screening instruments for problem gambling: A systematic review and meta-analysis
Authors: N.A. Dowling, S.S. Merkouris, S. Dias, S.N. Rodda, V. Manning, G.J. Youssef, D.I. Lubman, R.A. Volberg
Journal: Clinical Psychology Review (2019)

Non-gambling specialist services, such as primary care, alcohol and other drug use, and mental health services, are well placed to enhance the identification of people with gambling problems and offer appropriate generalist first level interventions or referral. Given time and resource demands, many of these clinical services may only have the capacity to administer very short screening instruments. This systematic review was conducted to provide a resource for health service providers and researchers in identifying the most accurate brief (1–5 item) screening instruments to identify problem and at-risk gambling for their specific purposes and populations. A systematic search of peer-reviewed and grey literature from 1990 to 2019 identified 25 articles for inclusion. Meta-analysis revealed five of the 20 available instruments met criteria for satisfactory diagnostic accuracy in detecting both problem and at-risk gambling: Brief Problem Gambling Screen (BPGS-2), NODS-CLiP, Problem Gambling Severity Index-Short Form (PGSI-SF), NODS-PERC, and NODS-CLiP2. Of these, the NODS-CLiP and NODS-PERC have the largest volume of diagnostic data. The Lie/Bet Questionnaire and One-Item Screen are also promising shorter options. Because these conclusions are drawn from a relatively limited evidence base, future studies evaluating the diagnostic accuracy of existing brief instruments across settings, age groups, and timeframes are needed.
Simultaneous Inhibition of Mcl-1 and Induction of DNA Damage Accumulation By Chidamide, a Novel Selective HDACi, Potentiates the Cytotoxicity of ABT-199 in Acute Myeloid Leukemia
Authors: Bing Xu, Kai Chen, Qianying Yang, Jie Zha, Haijun Zhao, Liying Feng, Xiaolei Chen, Guo Fu, Ken H. Young
Journal: Blood (2019)
Effect of Cyclosporine Inhalation Solution (CIS) on Lung Function and Inflammatory Biomarkers in Patients with Hematopoietic Stem Cell Transplant (HSCT) Associated Bronchiolitis Obliterans Syndrome (BOS)
Authors: Janhavi Athale, Nicole J Gormley, Robert Reger, Sara Alsaaty, Debra Reda, Tatyana Worthy, Ankit Saxena, Xin Tian, Richard W. Childs, Anthony F Suffredini
Journal: Blood (2019)
ACTR-68. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)
Authors: Garni Barkhoudarian, Michael Badruddoja, Nicholas Blondin, Ricky Chen, Sajeel Chowdhary, Charles Cobbs, Anthony Dowling, Paul Duic, John Paul Flores, Ekokobe Fonkem, Edward McClay, Louis Nabors, Michael Salacz, Brian Vaillant, Santosh Kesari
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND The EMulate Therapeutics Voyager system is an investigational non-sterile, non-invasive, non-thermal, non-ionizing, portable, home-use medical device that uses a specific, localized ultra-low radio frequency energy (ulRFE®) cognate for the treatment of brain cancer. METHODS This ongoing, open-label, multi-center study (NAT-101) is being conducted in the US and Australia in patients with recurrent GBM. There are 3 treatment groups: 32 patients treated with Voyager alone, 43 patients treated with Voyager + Investigator’s choice of anti-cancer therapy, and 21 patients treated with Voyager+lomustine+/-bevacizumab. The objective of the study is to assess if the Voyager is a safe and feasible treatment for recurrent GBM. The primary outcome measure is safety, assessed by the incidence and evaluation of adverse events (AEs) associated with the Voyager. The secondary outcome measures are progression-free survival and overall survival. RESULTS Enrollment is closed, and long-term treatment and follow-up is ongoing. 96 patients were enrolled and treated. 82 patients reported at least one AE, and 18 AEs were assessed as device-related (mild-moderate; 12 headache, 2 vomiting, 1 nausea, 1 confusion, 1 insomnia, and 1 skin irritation). 31 patients reported at least one serious AE, and none were assessed as device-related. 33% of patients treated with Voyager alone and 36% of patients treated with Voyager + chemotherapy were progression-free after 6 months. 58% of patients treated with Voyager alone and 60% of patients treated with Voyager + chemotherapy remained alive after 6 months; median overall survival is 7 months (95% CI=4.4±14.3) in patients treated with Voyager alone and 10 months (95% CI=6.7±11.5) in patients treated with Voyager + chemotherapy. CONCLUSIONS The Voyager system appears to be safe and feasible for the treatment of recurrent GBM. Given that therapy is delivered non-invasively and no device-related serious adverse events were reported, further prospective study of the investigational device is planned.
HOUT-27. HEALTHCARE RESOURCE UTILIZATION OF LEPTOMENINGEAL CARCINOMATOSIS IN THE UNITED STATES
Authors: Sarah E Hodges, Zidanyue Yang, Lefko Charalambous, Syed M Adil, Musa Kiyani, Alexis Musick, Ryan M Edwards, Beth Parente, Hui-Jie Lee, Katherine Peters, Peter Fecci, Shivanand Lad
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Leptomeningeal carcinomatosis (LC) represents a late complication of primary cancer spreading to the leptomeninges. METHODS The IBM MarketScan® Research databases were queried for adult patients diagnosed with LC between 2001 and 2015, secondary to four primary solid tumors (breast, lung, gastrointestinal, and melanoma). The primary outcome was overall healthcare resource utilization (HCRU) for each primary cancer subgroup, quantified as the total cost at baseline (1-year pre-LC diagnosis) and 30, 90, and 365 days post-LC diagnosis. The secondary outcome was interventional treatments for LC. RESULTS We identified 4,961 cases of LC (46% breast cancer, 35% lung cancer, 14% GI cancer, and 5% melanoma). The median baseline Elixhauser comorbidity index was lower for patients with LC secondary to breast cancer (19) relative to those with primary lung, GI, or melanoma (22). The overall median follow-up length was 66 days. The breast and lung cancer groups had the longest and shortest post-LC diagnosis follow-up at 84 and 51 days, respectively. Cost data demonstrated high baseline total costs for the year preceding LC diagnosis (median $117,219). Cumulative median service and medication costs at 365 days post-LC diagnosis were the highest for the GI subgroup ($167,768) and lowest for the lung cancer subgroup ($145,244). In the first 30 days post-diagnosis, 66.9% sought treatments of any kind: 40% radiotherapy, 28% therapeutic lumbar puncture (TLP), and 14% Ommaya insertion. Of the 747 (15%) patients surviving and continuously enrolled to 365 days post-diagnosis, 78.8% had at least one encounter for treatments: 58% radiotherapy, 30% TLP, and 15% Ommaya insertion. CONCLUSION In this large nationwide study of LC associated with four major primary cancers, breast cancer patients had the fewest comorbidities at baseline and the longest follow-up, while those with GI cancer had the highest cost both at baseline and one year after LC diagnosis.
Lower Hematopoietic Progenitor Cell Counts and Yields at Subsequent Donations Is Influenced By a Shorter Inter-Donation Interval between the First and Subsequent Mobilizations
Authors: Sandhya R. Panch, Brent R. Logan, Jennifer A. Sees, Bipin N. Savani, Nirali N. Shah, Jack W. Hsu, Michael A. Pulsipher, Galen E. Switzer, Bronwen E. Shaw, David F. Stroncek
Journal: Blood (2019)
IL-23 costimulates antigen-specific MAIT cell activation and enables vaccination against bacterial infection
Authors: Huimeng Wang, Lars Kjer-Nielsen, Mai Shi, Criselle D’Souza, Troi J. Pediongco, Hanwei Cao, Lyudmila Kostenko, Xin Yi Lim, Sidonia B. G. Eckle, Bronwyn S. Meehan, Tianyuan Zhu, Bingjie Wang, Zhe Zhao, Jeffrey Y. W. Mak, David P. Fairlie, Michele W. L. Teng, Jamie Rossjohn, Di Yu, Barbara Fazekas de St Groth, George Lovrecz, Louis Lu, James McCluskey, Richard A. Strugnell, Alexandra J. Corbett, Zhenjun Chen
Journal: Science Immunology (2019)

ICOS- and IL-23–mediated costimulation are important for driving in vivo activation of antigen-specific MAIT cells.
Integrated Transcriptomic and Proteomic Analyses of Inflammasome in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Authors: María Zurdo, Ana M Hurtado López, Tzu Hua Chen-Liang, Helios Martínez-Banaclocha, Laura Palomo, Félix López Cadenas, Eva Lumbreras, Blanca Xicoy, Lurdes Zamora, María Díez-Campelo, Francesc Sole, Pablo Pelegrín, Andres Jerez
Journal: Blood (2019)
SURG-22. CUSHING’S DISEASE: A DIFFICULT TO TREAT NEURO-ONCOLOGICAL CONDITION
Authors: Santanu Bora, Ashish Suri
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Cushing disease (CD) comprises a spectrum of clinical manifestations secondary to hypercortisolism due to ACTH-secreting pituitary adenoma. Transsphenoidal adenomectomy remains the standard treatment. Because of the significant rate of recurrence or persistence of CD, it is of interest to determine factors that may correlate with long-term outcomes following surgical intervention. OBJECTIVE The objective of our study is to determine the remission rate after surgery with special emphasis on factors affecting remission. METHODS Data of all patients undergoing surgery for CD from 2009 to 2017 was analyzed retrospectively. Transphenoidal resection was the preferred treatment with a recent trend in favor of endonasal endoscopic skull base approach. Post-operative cortisol level of &lt; 2 μg/dL was taken as remission and value between 2 and 5 μg/dL as possible remission. RESULTS 104 patients operated primarily for CD were included for analysis. 47 patients underwent microscopic surgery, 55 endoscopic surgery and two were operated trans-cranially. Remission was achieved in 76.47% of patients. In univariate analysis, factors significantly associated with remission were (1) type of surgery (p=0.01); endoscopy (88.23% remission) better than microscopy (56.6% remission) (2) postoperative day-1 morning cortisol (p=0.004) and; (3) postoperative day-1 morning ACTH (p=0.015). In multivariate analysis, however only postoperative day-1 cortisol was found to be significant as predictor of remission (p=0.02). CONCLUSION Postoperative plasma cortisol level is a strong independent predictor of remission and value less than 10.7µgm/dl can be taken as cut off for predicting remission. Remission provided by endoscopy appears to be significantly better than microscopic approach.
Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy
Authors: Amanda Winters, Jonathan A Gutman, Enkhtsetseg Purev, Brett M. Stevens, Shanshan Pei, Jeffrey Schowinsky, Diana Abbott, Andrew Hammes, Molly Nakic, Lindsey Lyle, Keri Halsema, Dwight Macero, Alex Hirose, Chelsey Boggs, Angie Falco, Natalie Monson, Shirstine Rahkola, Sarah Wright, Tyler D'Ovidio, Clayton Smith, Craig T Jordan, Daniel A Pollyea
Journal: Blood (2019)
INNV-22. TO TREAT OR NOT TO TREAT – TREATMENT OUTCOMES OF VERY ELDERLY GLIOBLASTOMA PATIENTS
Authors: Peter Baumgarten, Georg Prange, Patrick Harter, Marie-Therese Forster, Marlies Wagner, Joachim Steinbach, Volker Seifert, Christian Senft
Journal: Neuro-Oncology (2019)

Abstract OBJECTIVE The prognosis especially of older patients with glioblastoma is poor. Novel therapies are usually reserved for patients ≤65 years. As the population is growing older, the challenge remains as to how very elderly patients ≥75 years should be treated. Only limited outcome data exist for this patient subgroup. METHODS Between 2010 and 2018 we treated a total of 977 patients with glioblastoma at our institution. Of these, 144 patients were ≥75 years at diagnosis. The primary procedure was surgery or biopsy followed by adjuvant treatment, if possible. We retrospectively investigated progression-free and overall survival (OS) and looked at potential prognostic factors influencing survival, including Karnofsky performance score (KPS), surgical therapy, adjuvant therapy as well as MGMT promoter methylation status. RESULTS In our very elderly cohort, the median age was 79 years (range: 75–110). Biopsy only was performed in 108 patients, resection was performed in 36 patients. Median OS for the entire cohort was 5.9 months. Patients without adjuvant treatment fared worse than patients receiving either radiotherapy and/or chemotherapy (1.2 vs. 8.4 months, p&lt; 0.001). Multivariate analysis showed that KPS at presentation (≥70 vs. ≤60), surgery vs. biopsy, and MGMT status (methylated vs. non-methylated) were significantly associated with OS (6.3 vs. 3.9 months, p=0.002; 12.6 vs. 4.9 months, p=0.003; and 10.5 vs. 5.0 months, p=0.009, respectively). CONCLUSION For patients with glioblastoma ≥75 years, the natural course of the disease is devastating, and there is a negative treatment bias in these patients. Very elderly patients, too, benefit from multimodal treatment including microsurgical tumor removal. Treatment options and outcomes should be thoughtfully discussed with patients before treatment decisions are made.
Combined Inhibition of HDAC and AKT As a Strategy to Overcome Multi-Drug Resistance in Patients with Multiple Myeloma
Authors: Mitsuhito Hirano, Yoichi Imai, Takahiko Murayama, Kota Sato, Junichi Yamamoto, Takumi Ito, Muneyoshi Futami, Masaki Ri, Hiroshi Yasui, Noriko Gotoh, Shinsuke Iida, Tadao Ishida, Hiroshi Handa, Arinobu Tojo
Journal: Blood (2019)
Prolonged Progression-Free Survival Is Possible in Patients with Diffuse Large B-Cell Lymphoma Receiving > 1 Salvage Therapies before Autologous Stem Cell Transplant
Authors: Abigail G Kettle, Jeffrey Switchenko, Oscar Calzada, Anh Thuy Phan, Monique Farone, Michael Graiser, Christopher R. Flowers, Jonathon B. Cohen
Journal: Blood (2016)
Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase
Authors: Steven M. Horwitz, Neha Mehta-Shah, Barbara Pro, Eric D Jacobsen, Carla Casulo, Jonathan E. Brammer, Jeff Haney, Hagop Youssoufian, David T. Weaver, Michael Baglio, Jasminder Soto, Narayana Narasimhan, Jasmine Zain
Journal: Blood (2019)
Urinary Infection in Childhood
Authors: T. D. M. Marin
Journal: BMJ (1964)

Rule of Three" SIR,-Some official rebuke from the B.M.A. should surely be made to the Minister of Transport in his recommendation that three drinks should be taken before driving at Christmas.His "rule of three" must surely be the most imprudent advice given to motorists for many a decade.The rule of "none for the road" should always apply.-I am, etc., lo0n1(101 W.1. Guy
EphA4/Tie2 crosstalk regulates leptomeningeal collateral remodeling following ischemic stroke
Authors: Benjamin Okyere, William A. Mills, Xia Wang, Michael Chen, Jiang Chen, Amanda Hazy, Yun Qian, John B. Matson, Michelle H. Theus
Journal: Journal of Clinical Investigation (2019)

Leptomeningeal anastomoses or pial collateral vessels play a critical role in cerebral blood flow (CBF) restoration following ischemic stroke. The magnitude of this adaptive response is postulated to be controlled by the endothelium, although the underlying molecular mechanisms remain under investigation. Here we demonstrated that endothelial genetic deletion, using EphA4fl/fl/Tie2-Cre and EphA4fl/fl/VeCahderin-CreERT2 mice and vessel painting strategies, implicated EphA4 receptor tyrosine kinase as a major suppressor of pial collateral remodeling, CBF, and functional recovery following permanent middle cerebral artery occlusion. Pial collateral remodeling is limited by the crosstalk between EphA4-Tie2 signaling in vascular endothelial cells, which is mediated through p-Akt regulation. Furthermore, peptide inhibition of EphA4 resulted in acceleration of the pial arteriogenic response. Our findings demonstrate that EphA4 is a negative regulator of Tie2 receptor signaling, which limits pial collateral arteriogenesis following cerebrovascular occlusion. Therapeutic targeting of EphA4 and/or Tie2 represents an attractive new strategy for improving collateral function, neural tissue health, and functional recovery following ischemic stroke.
Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): The Experience at European Institute of Oncology (EIO)
Authors: Anna Vanazzi, Safaa Ramadan, Francesca De Lorenzi, Paola Arena, Enrico Derenzini, Mario Rietjens, Anna Rotili, Antuono Latronico, Laura Travaini, Emanuela Omodeo Sale', Daniela Malengo, Marianna Gerardi, Stefano Fiori, Valentina Tabanelli, Stefano A Pileri, Corrado Tarella
Journal: Blood (2019)